Abstract: Frequently encountered resistance mutations were for NRTIs: M184V (88%), TAMs (67%), T215F/I/V/Y (33%), and L74I/V (24%); for NNRTIs: K103N/S (74%), P225H (26%), and G190A/E/Q (24%).
HIV-1 Drug Resistance, Distribution of Subtypes, and Drug Resistance-Associated Mutations in Virologic Failure Individuals in Chengdu, Southwest China, 2014-2016.
Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda.
Discussion: This is anticipated given the fact that mutation K65R is highly selected for in TDF containing regimens and mutation L74V appears to be associated with poor treatment outcomes in TDF-based regimens.
Discussion: Within the NRTI class, individual mutations differed between these two regimens where mutations K65R (95.2%, p = 0.00005), Y115F (85.0%, p = 0.004) and L74V/I (82.6%, p = 0.004) appeared more frequently in the TDF/3TC/EFV.
HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study.
Synthesis and biological evaluation of a series of 2-(((5-akly/aryl-1H-pyrazol-3-yl)methyl)thio)-5-alkyl-6-(cyclohexylmethyl)-pyrimi din-4(3H)-ones as potential HIV-1 inhibitors.
Prevalence of HIV-1 Integrase Strand Transfer Inhibitor Resistance in Treatment-Naive Voluntary Counselling and Testing Clients by Population Sequencing and Illumina Next-Generation Sequencing in Taiwan.
Result: Among the 38 patients who had both sanger sequencing and Illumina NGS data, 5% (2/38) had NRTI/NNRTI/PI resistance and none had INSTI resistance (one had an L74V substitution) by sanger sequencing however Illumina NGS for INSTI resistance detected four more INSTI resistance ( 1%) associated mutations with low frequency (G163R 3.25%, S153Y 1.36%, S153F 3.21% and Y143H 2.06%) (Table 5).
HIV mutation literature information.
PMID: 
2021
Genome
Browser Board
Co-occurred Entities
Filtrator
ViMRT